# A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months

> **NCT01000311** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 529 (actual)

## Conditions studied

- Meningococcal Disease

## Interventions

- **BIOLOGICAL:** MenACWY-CRM
- **BIOLOGICAL:** DTaP-IPV/Hib
- **BIOLOGICAL:** HBV
- **BIOLOGICAL:** PCV
- **BIOLOGICAL:** MMR

## Key facts

- **NCT ID:** NCT01000311
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 529 (ACTUAL)
- **Last updated:** 2014-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01000311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01000311, "A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01000311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*